U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07069595) titled 'PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease' on July 07.
Brief Summary: This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advances in ctDNA assays have improved both the sensitivity and reliability of molecular residual disease (MRD) detection to enable real-time measurement with clinical-grade assays.
The primary objective of this study will be to evaluate ctDNA-based MRD stat...